12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Flutiform fluticasone/formoterol regulatory update

The Scottish Medicines Consortium recommended the use of flutiform fluticasone/formoterol from Mundipharma to treat asthma in patients inadequately controlled on an inhaled corticosteroid (ICS) with "as required" therapy with short-acting adrenergic receptor beta 2 agonists (LABA)...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >